1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
SBIR Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) (PA-27-101) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). This 'Bridge Award' supports small businesses that have completed a Phase II SBIR or STTR project and require additional, larger support to advance their promising results towards commercialization.
It is designed to help companies cross the 'Valley of Death' in late-stage development of therapeutics, medical devices, and innovative biologics.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small business concerns that have a Phase II SBIR or STTR in hand. Confirm the full requirements in the official notice before applying.
SBIR Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) (PA-27-101) is funded by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). This program funds small businesses to conduct research and development with commercial potential in health-related technologies. It supports early feasibility through later-stage commercialization.
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). This parent announcement supports small businesses in developing innovative health-related technologies, from early feasibility through later-stage commercialization. Applications are accepted three times a year.
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). This funding opportunity invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleUSDA and HHS announced Harvest to Hallways on August 24, 2026: $50M in new cafeteria infrastructure funding on top of $20M in Equipment Assistance Grants, up to $25M more in Patrick Leahy Farm to School awards for FY2026, and $30M in HHS nutrition research. Each pot has a different applicant, a different route, and a different timeline. Here is how to position for all three before the notices post.
Read articleCDC-RFA-EH-27-0074 posted as a forecast September 22, 2026: 6 expected awards at $750,000 to $900,000. That is flat funding against the expiring cycle — and the only proven way in is the consortium model Arizona used to bring three states under one award.
Read article